2
Participants
Start Date
February 29, 2012
Primary Completion Date
November 30, 2017
Study Completion Date
November 30, 2017
ADHD Medication
For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.
Omega-3 Fatty Acids
Omega-3 Fatty Acids prescribed to participants randomized to active medication. They may be randomized to receive 1060mg of EPA (2 capsules containing 530mg EPA and 137mg DHA). Dosage will remain constant throughout study.
Massachusetts General Hospital, Boston
Massachusetts General Hospital
OTHER